Evaluation of Hospital Healthcare Utilization and Costs Among Hospitalized Venous Thromboembolism (VTE) Patients Treated With Apixaban or Warfarin in the United States
Latest Information Update: 11 Dec 2019
Price :
$35 *
At a glance
- Drugs Apixaban (Primary) ; Warfarin
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 07 Dec 2019 According to a Bristol-Myers Squibb media release, results (n=14,086) from this study were presented at the American Society of Hematology (ASH) Annual Meeting.
- 07 Dec 2019 Results presented in a Bristol-Myers Squibb media release
- 31 Oct 2019 New trial record